<DOC>
	<DOCNO>NCT01489111</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial evaluate haemostatic effect NNC 0129-0000-1003 surgical procedure subject haemophilia A .</brief_summary>
	<brief_title>Evaluating Haemostatic Effect NNC 0129-0000-1003 During Surgical Procedures Subjects With Haemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject . ) Ongoing participation pathfinder™2 ( NN70883859 ) pathfinderTM 4 ( NN70883861 ) trial receive great equal 5 dos N8GP Undergoing major surgery require daily monitoring FVIII : C ( FVIII activity ) wound status least 3 day The patient and/or Legally Acceptable Representative ( LAR ) capable assess bleed episode , keep eDiary , capable home treatment bleed episode otherwise capable follow trial procedure Known suspect hypersensitivity trial product include allergy hamster protein relate product Previous withdrawal pathfinder™2 ( NN70883859 ) pathfinderTM 4 ( NN70883861 ) trial administration trial product , except interruption due inclusion pathfinderTM 3 trial ( NN70883860 ) The receipt investigational medicinal product ( except N8GP ) within 30 day prior enrolment trial . ( For Brazil , : Participation previous clinical trial within one year prior screen trial ( Visit 1 ) , unless direct benefit research subject , Investigator 's discretion ) FVIII inhibitor least 0.6 BU ( Bethesda Units ) /mL screen Previous arterial thrombotic event ( e.g . myocardial infarction intracranial thrombosis ) previous deep venous thrombosis pulmonary embolism ( define available medical record ) Immune modulate chemotherapeutic medication Any disease ( liver , kidney , inflammatory mental disorder include ) condition , accord Investigator 's judgement , could imply potential hazard patient , interfere trial participation trial outcome Unwillingness , language barrier preclude adequate understanding and/or cooperation</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>